Scientist, Discovery Science at Abata Therapeutics

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, OncologyIndustries

Requirements

PhD in Molecular/Cell Biology, Biochemistry, Cancer Biology, Pharmacology or related field (or MS/BS with commensurate depth of industry experience)
5+ years of hands-on lab experience with a range of relevant research techniques including cell-based assays and molecular biology
In vivo mouse experience is strongly preferred
Understanding of the drug development process from target identification to marketing

Responsibilities

Participate in key discovery workstreams from target validation through early pharmacology; design clear, decision-driving experimental plans and timelines
Interrogate mechanism using genetic perturbation (e.g. CRISPR/Cas9, RNAi), rescue, pathway mapping, and combination studies aligned with CIN biology
Develop and optimize cellular assays to quantify phenotype and mechanism
Build translationally relevant target-engagement and PD assays to enable SAR and inform dose/PK–PD modeling for in vivo studies
Track record of successfully managing external projects with CRO’s from scoping to final data delivery
Work effectively with colleagues across the team to participate in adjacent discovery-related efforts
Provide clear updates to Discovery, Preclinical, and Leadership; write technical reports, support patent filings, and prepare data packages for milestones

Skills

chromosomal instability

CIN biology

target validation

mechanism of action

preclinical development

experiment design

oncology

KIF18A inhibitors

cell biology

molecular biology

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free